Erratum: PharmGKB summary: very important pharmacogene information for CYP1A2 (Pharmacogenetics and Genomics (2012) 22 (73-77) DOI: 10.1097/FPC.0b013e32834c6efd);PharmGKB summary: Very important pharmacogene information for CYP1A2

Pharmacogenetics and Genomics

Volumn 22, Issue 1, 2012, Pages 73-77

  Thorn, Caroline F ^a   Aklillu, Eleni ^b   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

caffeine; CYP1A2; pharmacogene; pharmGKB

Indexed keywords

CAFFEINE; CHLORPROMAZINE; CLOPIDOGREL; CLOZAPINE; CYP1A2 1A; CYP1A2 1C; CYP1A2 1F; CYP1A2 1K; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; FLUPHENAZINE; FLUVOXAMINE; NEUROLEPTIC AGENT; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PRIMAQUINE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME REGULATION; FATIGUE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR DEPRESSION; PARKINSON DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

EID: 83655163790     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000387     Document Type: Erratum

References (50)

1. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009; 11:481-494.
2. Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, Kusano K, et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 2006; 69:1924-1930. (Pubitemid 43894309)
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423. (Pubitemid 24229655)
4. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392:1093-1108.
5. Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12:473-478. (Pubitemid 34913530)
6. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010; 1:129.
7. Jorge-Nebert LF, Jiang Z, Chakraborty R,Watson J, Jin L, McGarvey ST, et al. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 2010; 31:27-40.
8. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9:625-637. (Pubitemid 351803920)
9. Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K, Yamazoe Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobioticresponsive elements. Biochem Pharmacol 2008; 76:139-145.
10. Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 50-flanking region. Biochem Pharmacol 2010; 79:261-269.
11. Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010; 20:647-664.
12. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63:537-546. (Pubitemid 46684487)
13. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-514. (Pubitemid 23161197)
14. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011; 7:e1002033.
15. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20:2071-2077.
16. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29:319-326.
17. Ozdemir V, KalowW, Okey AB, Lam MS, Albers LJ, Reist C, et al. Treatmentresistance to clozapine in association with ultrarapid CYP1A2 activity and the C-A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001; 21:603-607. (Pubitemid 33116661)
18. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24:214-219. (Pubitemid 38380846)
19. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999; 21:580-582. (Pubitemid 29468329)
20. Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52:531-533.
21. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res 2009; 124:588-591.
22. Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 2008; 64:381-385. (Pubitemid 351322359)
23. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C A polymorphism. Eur J Clin Pharmacol 2010; 66:697-703.
24. Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP nomenclature. JAMA 2006; 296:764-765. (Pubitemid 44223097)
25. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295:1135-1141. (Pubitemid 43352342)
26. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002; 54:540-543. (Pubitemid 35356882)
27. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-Izaki K, et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003; 73:468-474. (Pubitemid 36549830)
28. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64:659-669. (Pubitemid 37048569)
29. Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol 2006; 62:23-28. (Pubitemid 43106312)
30. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a CA polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449. (Pubitemid 29161279)
31. Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002; 54:504-510. (Pubitemid 35356876)
32. El-Sohemy A, Cornelis MC, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype and risk of myocardial infarction. Genes Nutr 2007; 2:155-156.
33. Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 2011; 18:756-765.
34. Tan EK, Chua E, Fook-Chong SM, Teo YY, Yuen Y, Tan L, et al. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenet Genomics 2007; 17:1001-1005. (Pubitemid 350293800)
35. Facheris MF, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Rocca WA, et al. Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord 2008; 23:2033-2040.
36. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010; 10:20-29.
37. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5:410-417. (Pubitemid 30455955)
38. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13:544-556. (Pubitemid 351556033)
39. Boke O, Gunes S, Kara N, Aker S, Sahin AR, Basar Y, et al. Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA Cell Biol 2007; 26:527-531. (Pubitemid 47263198)
40. Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27:328-332. (Pubitemid 43357029)
41. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5:60-69. (Pubitemid 40220619)
42. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105:498-501. (Pubitemid 32729815)
43. Tay JK, Tan CH, Chong SA, Tan EC. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1297-1302. (Pubitemid 47081318)
44. Lin KM, Tsou HH, Tsai IJ, Hsiao MC, Hsiao CF, Liu CY, et al. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics 2010; 11:1535-1543.
45. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003; 55:321-324. (Pubitemid 36390765)
46. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003; 55:68-76. (Pubitemid 36110841)
47. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 50-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem1999; 125:803-808. (Pubitemid 29192503)
48. Matsumoto C, Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004; 14:209-213. (Pubitemid 40054347)
49. Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:24-33.
50. Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen AC, Bertilsson L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009; 9:208-217.